May 2, 2023 09:00AM

Nov 10, 2022 07:30AM

Mar 14, 2022 04:15PM

Feb 28, 2022 09:00AM

Feb 22, 2022 04:32PM

Feb 22, 2022 04:30PM

Jan 31, 2022 07:00AM Sigilon Therapeutics to Present Preclinical Data at the 18th Annual WORLDSymposium™ on Lysosomal Diseases, MPS-1 and MPS-6

Dec 13, 2021 05:01PM

Dec 13, 2021 05:00PM

Nov 30, 2021 07:44AM

Nov 29, 2021 07:01AM

Nov 29, 2021 07:00AM

Nov 10, 2021 04:15PM

Nov 10, 2021 04:15PM Sigilon Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights

Sep 9, 2021 07:00AM

Aug 10, 2021 07:00AM

Aug 10, 2021 07:00AM

Jul 9, 2021 07:31AM

Jul 9, 2021 07:30AM

May 10, 2021 04:05PM

May 10, 2021 04:05PM Sigilon Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights

Mar 18, 2021 04:05PM

Mar 18, 2021 04:05PM

Mar 5, 2021 07:00AM

Mar 5, 2021 07:00AM

Mar 5, 2021 07:00AM

Dec 17, 2020 07:00AM

Dec 17, 2020 07:00AM Sigilon Therapeutics Receives Orphan Drug Designation for SIG-005 for the Treatment of Mucopolysaccharidosis Type I

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All